Platform development at Ypsomed begins independently of specific customer projects. This proactive approach allows us to invest early in device concepts and core technologies, ensuring our platforms are ready to support customer programs without the need for entirely new development efforts. Customers benefit from shorter lead times and reduced initial risk.

Usability and human factors studies, along with functional testing, are integrated throughout the development process. Platforms are evaluated and refined with feedback from representative user groups, and findings are available to support customer regulatory activities. This ensures our platforms are patient-centric and compliant with global usability and safety standards from the outset, with pre-validated components reducing time to market significantly.

All platform development functions are centralized at our headquarters in Burgdorf, Switzerland. This setup streamlines collaboration across design, human factors, regulatory, and clinical support teams.

Our expertise as a consultant in drug delivery is highly valued by all our customers. In particular, companies new to the self-injection subcutaneous drug delivery market appreciate guidance on selecting, customizing, and validating injection devices. Customers benefit from hands-on support, technical data, and access to automation solutions from a trusted partner throughout the product lifecycle.